Wire · opportunities
Veterans Affairs continues to drive federal psychedelics push; New FDA guidance
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 August 2026 · Fusion42 review
The U.S. Department of Veterans Affairs is advancing federal psychedelic research with a focus on ibogaine and psilocybin treatments, including a multi-site trial for treatment-resistant depression using Compass Pathways' COMP360. The FDA has issued updated guidance on clinical trials for psychedelic drugs, clarifying safety assessments, trial populations, and control group recommendations to better support development efforts.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face clearer trial rules for psychedelics driven by FDA and Veterans Affairs cooperation which opens a path for faster federal trial approvals. This is a direct channel to government-backed validation that can speed up your go-to-market if you develop psychedelic therapies.
◆ Coverage
1 source · 15 Aug 2026
◆ Related on Wire
◆ Topics